RESEARCH

Validating the Future of Veterinary Medicine

5 July 2025
Pointer Research Team, with independent analysis by David Kincaid, Dedekind Cut Labs
Intro to a healthier, software-based validated screening for dogs.

The application of artificial intelligence in veterinary medicine presents new opportunities to improve risk prediction and advance preventive care. To assess the reliability of our predictive screening platform, Pointer commissioned an independent evaluation from Dedekind Cut Labs, an external consultancy with expertise in veterinary informatics and AI validation.

At Pointer, we've developed a non-invasive, software-based screening platform designed to detect health risks in dogs before symptoms emerge. To ensure its reliability in clinical settings, we partnered with Dedekind Cut Labs, a veterinary AI evaluation firm led by David Kincaid, to conduct an independent, comprehensive analysis of Pointer's predictive power. This evaluation was conducted to determine the predictive performance of Pointer across a broad set of health conditions, using real-world clinical data from veterinary practices.

A New Standard in Predictive Screening

The evaluation examined Pointer's ability to predict disease risk across a large, diverse dataset. The assessment focused on the model's generalizability and its ability to deliver clinically meaningful predictions.

The dataset included:

  • 48 distinct veterinary health conditions, covering metabolic, cardiovascular, renal, endocrine, and infectious categories.
  • 18,189 dogs across 137,790 patient visits, encompassing a range of breeds, ages, and clinical presentations.
  • Comprehensive historical records sourced from anonymized, routine clinical visits in practice settings.

Findings and Performance Highlights

The analysis demonstrated strong predictive capabilities across the evaluated conditions, with a particular focus on statistical rigor and clinical relevance. Predictions were evaluated using Likelihood Ratios Positive (LR+), which quantify the increase in odds of disease following a positive screening result.

  • Average LR+ of 36.9× across all conditions, indicating substantial predictive strength.
  • Highest-performing conditions included:
    • Pancreatitis: LR+ of 367.
    • Urinary Tract Infections: LR+ of 41.
    • Heart Murmur: LR+ of 30.

These findings suggest that a positive Pointer screening result is associated with a markedly increased risk of subsequent clinical diagnosis, often by an order of magnitude or more.

“Pointer's predictive performance exceeds most published veterinary or human AI models, with clear clinical applicability.”

— David Kincaid, Dedekind Cut Labs

Evaluation Methodology

The evaluation followed established best practices in predictive modeling and veterinary epidemiology. Temporal validation methods were applied to ensure predictions were made on future events, reducing the risk of data leakage and ensuring clinically relevant performance estimates.

  • Temporal validation to test predictive performance against future diagnoses.
  • Robust statistical techniques to account for missing data and right-censoring.
  • Model testing was performed without access to lifestyle or environmental variables to maintain conservative estimates of performance.

Clinical Applications and Practice Outcomes

Pointer's utility extends beyond statistical metrics. The platform is designed for seamless integration into veterinary workflows, with the goal of supporting earlier interventions and better patient outcomes.

  • One-click Screening: Full patient risk assessment requires only a single clinician input.
  • Rapid Results: Screening process completes in under 17 seconds.
  • Impact on Clinical Practice: Clinics using Pointer reported a 30% increase in preventive care interventions during wellness exams.

Ongoing Research and Transparency Commitments

This independent analysis represents an initial milestone in Pointer's scientific validation process. The platform will continue to be evaluated through additional studies, including prospective trials and broader applications of clinical, lifestyle, and environmental data.

  • Prospective, multi-center validation studies are underway.
  • Plans to publish full methods and results in peer-reviewed journals.
  • Continuous refinement to enhance explainability and transparency for clinical users.

About Dedekind Cut Labs

Dedekind Cut Labs is an independent veterinary AI consultancy, specializing in the evaluation of predictive technologies for clinical use. Led by David Kincaid, the firm brings extensive expertise in epidemiology, veterinary informatics, and statistical modeling.